OCSE:ALK B (Denmark)
Business Description
Alk-Abello A/S
NAICS : 325412
SIC : 2834
Boge Alle 6-8, Horsholm, DNK, DK-2970
Compare
Compare
Traded in other countries / regions
ALK B.Denmark
•
4AJ0.Germany
•
0OIR.UK
•
AKABY.USA
Description
Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.31 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | 0.99 | |||||
Interest Coverage | 26.53 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 9.76 | |||||
Beneish M-Score | -2.31 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.9 | |||||
3-Year EBITDA Growth Rate | 51.6 | |||||
3-Year Book Growth Rate | 2.4 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 50.94 | |||||
9-Day RSI | 52.64 | |||||
14-Day RSI | 54.06 | |||||
6-1 Month Momentum % | 12.96 | |||||
12-1 Month Momentum % | -5.81 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.86 | |||||
Quick Ratio | 0.98 | |||||
Cash Ratio | 0.14 | |||||
Days Inventory | 275.39 | |||||
Days Sales Outstanding | 54.83 | |||||
Days Payable | 28.75 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.6 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 62.46 | |||||
Operating Margin % | 9.42 | |||||
Net Margin % | 7.52 | |||||
ROE % | 9.09 | |||||
ROA % | 5.43 | |||||
ROIC % | 6.85 | |||||
ROC (Joel Greenblatt) % | 13.74 | |||||
ROCE % | 9.14 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 98.82 | |||||
PE Ratio without NRI | 98.82 | |||||
Shiller PE Ratio | 283.22 | |||||
Price-to-Owner-Earnings | 88.81 | |||||
PEG Ratio | 141.17 | |||||
PS Ratio | 7.42 | |||||
PB Ratio | 8.31 | |||||
Price-to-Tangible-Book | 10.08 | |||||
Price-to-Free-Cash-Flow | 192.85 | |||||
Price-to-Operating-Cash-Flow | 63.62 | |||||
EV-to-EBIT | 78.22 | |||||
EV-to-EBITDA | 49.17 | |||||
EV-to-Revenue | 7.55 | |||||
EV-to-FCF | 195.78 | |||||
Price-to-Projected-FCF | 16.5 | |||||
Price-to-Median-PS-Value | 2.12 | |||||
Price-to-Peter-Lynch-Fair-Value | 4.04 | |||||
Price-to-Graham-Number | 6.69 | |||||
Price-to-Net-Current-Asset-Value | 133.8 | |||||
Earnings Yield (Greenblatt) % | 1.28 | |||||
Forward Rate of Return (Yacktman) % | 19.69 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | 4,227 | ||
EPS (TTM) (kr) | 1.446 | ||
Beta | 1.4 | ||
Volatility % | 44.68 | ||
14-Day RSI | 54.06 | ||
14-Day ATR (kr) | 5.747283 | ||
20-Day SMA (kr) | 143.06 | ||
12-1 Month Momentum % | -5.81 | ||
52-Week Range (kr) | 113.2 - 175 | ||
Shares Outstanding (Mil) | 220.21 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 8 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Alk-Abello A/S Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |